INTRODUCTION
S entinel lymph node (SL) is the first lymph node that receives lymphatic drainage of a particular primary tumor location 1 . Cabanas1, in 1977, studied penile adenocarcinoma patients and stablished for the first time the technique to perform biopsy of sentinel lymph node (BSL). In order to improve identification rate of SB in melanoma patients, Krag et al. 2 , in 1993, used Technetium 99 (Tc99) successfully. Later, in 1994, Giuliano et al. 3 , using patent blue as marker for SL in breast cancer, introduced the concept of biopsy of SL (BSL) in daily practice. In 2003, Veronesi et al. 4 stated that BSL is a safe and accurate method to evaluate axillary metastasis in women with small breast tumors. Nowadays, BSL replaced axillary lymphadenectomy at initial breast cancer staging in patients with clinically negative axilla 5 .
The association of Tc99 and patent blue marker was more accurate to identify BSL 6, 7 . Other markers have been used in the identification of SB during surgical procedure, such as methylene blue, patent blue and isosulfan 8 . However, those substances, in a recent literature review, present a high number of hypersensitivity reactions 9, 10 . Patent blue may cause subtle adverse effects, such as cutaneous rash, or even severe, such as anaphylaxis 11, 12 . Methylene blue may also cause severe reactions, including skin and fat necrosis at the site of injection 13 . Anaphylactic reactions with isosulfan and patent blue in patients submitted to BSL vary from 0.6% to 2.7% 14 .
In 2009, Pinheiro et al. 15 marker without adverse reactions and an alternative to current markers.
In 2015, Vasques et al. 16 introduced the studies with hemosiderin in initial human breast cancer (T1/ T2) with clinically negative axilla, and success (identification) and agreement rates of 100% compared to gold standard (Tc99). In view of those results, the present study proposal was to evaluate the efficacy of hemosiderin to identify sentinel lymph node in patients with locally advanced breast cancer (T2>4cm/T3/T4), compared to TC99 gold standard test. One week before the beginning of the study, all participants were submitted to clinical evaluation and pre-operatory laboratory tests, being fit for surgical procedure. Iron profile was also previously evaluated by complete blood count, serum iron, serum ferritin, transferrin saturation and iron total ligand capacity.
METHODS

Sampling and selection criteria
Preparation of marker rich in hemosiderin
Hemosiderin preparation for use at the study was obtained in a 16ml of peripheral blood sample 48 hours before surgery. Collected blood was maintained in two aseptic BD Vacutainer® tubes containing buffered Sodium Citrate. Next, the tubes were centrifuged at 2000rpm at 22 o C for ten minutes. Centrifuged material were distributed in three layers: the superior and intermediate (serum) were discharged and the inferior (red cells) was diluted with equal volume that was removed, and manually homogenized with saline in a laminar flow chamber. The obtained solution was again centrifuged (3800rpm for three minutes) and two layers were produced. The first was discharged and the volume was 
Procedure: biopsy of sentinel lymph node (BSL)
Patients were submitted to BSL, incising the 
Statistical analysis
RESULTS
Eighteen patients were submitted to BSL with hemosiderin according to described method. Mean age of patients was 48.2 years and 63.7% were pre-meno- pausal. At histology, all patients had invasive tumor, 17 with ductal tumor. T3 staging was the most frequent and 55% of patients had a positive axillary study at pathology (Table 1 ). There were no adverse effects and/ or allergic reactions, surgical infection or toxicity in all patients submitted to BSL with hemosiderin in this study.
At surgery, marking with hemosiderin was extremely satisfactory for visual identification and differentiation of SL from all other axillary lymph nodes (Figure 3 ).
Efficacy of BSL with hemosiderin was compared to gold-standard technique with Tc99 and the results were satisfactory. Identification rate of SL was 88.9% and a medium of two SB were found by patient. The study identified SL marked with hemosiderin in 83.3% of patients (n=15) and, compared to Tc99 identification, agreement was observed in 94.4% of studied patients, Kappa index =0.77 and p=0.001 (Figure 4) . When patients submitted to neoadjuvant chemotherapy followed by BSL are studied, iden-tification rate may be lower due to chemotherapy effects. Breslin et al. study 18 found an identification rate of 84%. Other studies showed identification rates varying from 85% to 98% (as quoted by Xing et al. study 19 ). Jones et al. 20 compared BSL before and after neoadjuvant chemotherapy and found a respective rate of identification of 100% and 80.6%, and a higher false negative rate in post-chemotherapy group (11%). In the series studied by Cox et al. 21 , including 89 patients with locally advanced breast cancer, stratified in two groups (positive and negative axilla), it was observed that BSL before chemotherapy had an adequate accuracy for negative axilla.
Papa et al. study 22 compared sentinel lymph node biopsy before and after chemotherapy and the iden- It is observed a tendency to avoid the use of radioisotope and patient exposure to radiation, and of patent blue, due to potentially severe adverse reactions. In facilities with adequate nuclear medicine departments, costs are elevated (particularly of gamma-probe) and radioisotope half-life is short.
The studied autologous marker was safely injected 48 hours before surgery, without any adverse reaction.
Our study suggests that the use of hemosiderin as an autologous marker is useful at daily clinical practice, to identify sentinel lymph node in locally advanced breast tumors.
Objetivo: verificar a taxa de concordância na identificação do linfonodo sentinela utilizando um marcador autólogo rico em hemossiderina e o Tecnécio 99 (Tc99) em casos de câncer de mama localmente avançados. Métodos: ensaio clínico fase 1, do tipo prospectivo, não randomizado, em 18 pacientes portadoras de câncer de mama com axila clinicamente negativa em estádio T2=4cm, T3 e T4. As pacientes foram submetidas à injeção sub-areolar de um marcador autólogo rico em hemossiderina 48 horas antes do procedimento cirúrgico para biópsia do linfonodo sentinela, e sua taxa de identificação foi comparada, no intraoperatório, com o marcador radioativo Tc99 (padrão-ouro). A concordância entre os métodos foi estabelecida pelo índice de Kappa. Resultados: a taxa de identificação do linfonodo sentinela foi de 88,9%, com uma média de dois linfonodos sentinelas por paciente. O estudo identificou os linfonodos sentinelas corados com hemossiderina em 83,3% dos casos (n=15), quando comparados com a taxa de identificação do Tc99, tendo sido observada concordância em 94,4% dos casos estudados. Conclusão: o marcador autólogo rico em hemossiderina se mostrou eficaz na identificação do linfonodo sentinela em casos de câncer de mama localmente avançado.
Descritores: Neoplasias da Mama. Biópsia de Linfonodo Sentinela. Hemossiderina. Tecnécio.
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